The race is under way to make faster, cheaper and better GLP-1 drugs that will go beyond reducing obesity levels to treating ...

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...

T2D has been associated with an increased risk of CV mortality and GLP-1RAs are being increasingly used as a T2D and obesity ...

In its annual 'Measuring the Return from Pharmaceutical Innovation' report based on the top 20 pharma companies by 2020 R&D ...

Demand for GLP-1 drugs is causing spending on traditional drugs to grow at a faster clip than spending on specialty drugs, according to new research. That could put further stress on employers and ...

By targeting areas of the brain responsible for reward signals from food, GLP-1 drugs might also reduce the rewards people get from other things, such as addictive substances. But what does the ...

Preoperative GLP-1RA use was not significantly associated with an increased risk for postoperative aspiration pneumonia or acute respiratory failure.

GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.

The problem is that these Glucagon-like peptide-1 (GLP-1) drugs were initially approved to treat type 2 diabetes, and later received approval as weight-loss medications, researchers said.

Spending on GLP-1 drugs continues to rise, after outpacing trends among specialty drugs for the first time in 2023, according to a new report from Evernorth. Pharmaceutical spending overall has ...

However, if GLP-1RA drugs are excluded from the calculation, this number drops to $370m – indicating their substantial market influence. Among the 20 assets that had their peak sales forecast by ...